Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: A first "real-life" experience in primary gastroenterology centers in Italy

Annals of Gastroenterology

Volumn 27, Issue 4, 2014, Pages 369-373

  Tursi, Antonio ^a   Elisei, Walter ^b   Picchio, Marcello ^c   Penna, Antonio ^d   Forti, Giacomo ^e   Giorgetti, Gian Marco ^f   Faggiani, Roberto ^g   Zampaletta, Costantino ^g   Pelecca, Giorgio ^g   Brandimarte, Giovanni ^h  

^a ASL BAT   (Italy)

^b ASL Roma H   (Italy)

^c Division of Surgery   (Italy)

^d San Paolo   (Italy)

^e SANTA MARIA GORETTI HOSPITAL   (Italy)

^f S EUGENIO HOSPITAL   (Italy)

^g Division of Gastroenterology Belcolle Hospital   (Italy)

^h Cristo Re Hospital   (Italy)

Author keywords

Adalimumab; Clinical practice; Clinical remission; Mucosal healing; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; INFLIXIMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; COLON RESECTION; COLONOSCOPY; COMMUNITY ACQUIRED PNEUMONIA; CROHN DISEASE ACTIVITY INDEX; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEALING; HUMAN; INFECTION; INFUSION RELATED REACTION; ITALY; MAINTENANCE DRUG DOSE; MALE; MUCOSAL HEALING; OPEN STUDY; PRIMARY MEDICAL CARE; REMISSION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT INDICATION; ULCERATIVE COLITIS; VIRUS PNEUMONIA;

EID: 84925260231     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Dignass A, Eliakim R, Magro F, et al. Second European evidencebased consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012;6:965-990.
2. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030.
3. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-987.
4. Travis S, Van Assche G, Dignass A, Cabre E, Gassull MA. On the second ECCO Consensus on Crohn’s disease. J Crohns Colitis 2010;4:1-6.
5. D’Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011;106:199-212.
6. Orlando A, Armuzzi A, Papi C, et al. Italian Society of Gastroenterology; Italian Group for the study of Inflamatory Bowel Disease. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2011;43:1-20.
7. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004;2:542-553.
8. ® Product Monograph. Abbott.
9. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-333.
10. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007;132:52-65.
11. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Int Med 2007;146:829-838.
12. Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease. Aliment Pharmacol Ther 2010;31:1296-1309.
13. Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008;28:966-972.
14. Afi f W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009;15:1302-1307.
15. Gies N, Kroeker KI, Wong K, et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a singlecentre cohort. Aliment Pharmacol Ther 2010;32:522-528.
16. Taxonera C, Estelles J, Blanco I, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther 2011;33:340-348.
17. Ferrante M, Karmiris K, Compernolle G, et al. Efficacy of adalimumab in patients with ulcerative colitis: restoration of serum levels after dose escalation results in a better long-term outcome. Gut 2011;60(Suppl 3):A72.
18. McDermott E, Murphy S, Keegan D, et al. Efficacy of adalimumab as a long term maintenance therapy in ulcerative colitis. J Crohns Colitis 2013;7:150-153.
19. Armuzzi A, Biancone L, Daperno M, et al. Adalimumab in active ulcerative colitis: a “real-life” observational study. Dig Liver Dis 2013;45:738-743.
20. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-787.
21. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-265.
22. Regime di rimborsabilita e prezzo a seguito di nuove indicazione terapeutiche del medicinale per uso umano Humira (adalimumab). Gazzetta Ufficiale della Repubblica Italiana 2014;98:12-13.
23. Sutherland LR, Martin F, Greer S, et al. 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92:1894-1898.
24. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-1629.